Navigation Links
Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
Date:9/13/2013

SEATTLE, Sept. 13, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient's adaptive immune system to fight infection after a cord blood transplant. The phase II study follows promising phase I results presented at ASCO 2012 showing a statistical correlation between low diversity of infection-fighting immune cells (T-cells) and high likelihood of death from complications, including infection, during the first year after transplant.

(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)

It is widely recognized that the ability for a cord blood transplant recipient to reconstitute a healthy immune system is critical for overall survival. However, the existing standard of care only measures absolute T-cell counts, which did not show a correlation to the risk of infection in the phase I study.

"We are delighted to be the recipients of this important grant which aims to provide clinicians with a test to reliably identify patients who are not reconstituting a healthy, diverse immune system after transplant," said Chad Robins, CEO and Founder of Adaptive Biotechnologies.

"Identifying patients at risk for infection early after transplant is something that we strive to do in the clinic, but the current standard of using total T-cell counts seems to be suboptimal," said  Dr. Colleen Delany, Cord Blood Transplant Program Director at The Fred Hutchinson Cancer Center.  "We are pleased to be leading this effort to identify a better way to measure immunity and ultimately increase overall survival for our transplant patients."

Adaptive's Next-Generation Sequencing platform, immunoSEQ™, will be used in the phase II study to measure T-cell and B-cell diversity. The study will be conducted prospectively over a three-year period on approximately 400 cord blood transplant recipients from five of the top transplant centers in the United States. Patients' blood will be drawn at several time points after transplant and shipped to Adaptive's CLIA-certified centralized laboratory in Seattle. The company's immunosequencing platform and accompanying bioinformatics tools will be used to calculate a precise measure of diversity for each patient at each time point. While cord blood transplant serves as an ideal model to confirm the importance of immune reconstitution because of the higher incidence of infectious morbidity and mortality compared to other tissue sources used for stem cell transplants, the results should apply to all stem cell transplantation procedures.

This test of immunocompetence will add to Adaptive's portfolio of products that use immunosequencing for prognosis, diagnosis, and monitoring of cancer patients. The company's first clinical application, clonoSEQ™, is for monitoring Minimal Residual Disease ("MRD") in blood-based cancers.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation ("Adaptive" or the "Company") is a development stage biotechnology company that utilizes its proprietary immune profiling technology to discover, develop, and commercialize oncology diagnostics. The Company leverages advances in next generation sequencing ("NGS") to profile T-Cell and B-Cell Receptors ("TCRs" and "BCRs").  This breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company's first clinical application, clonoSEQ™, is for monitoring Minimal Residual Disease ("MRD") in blood-based cancers.  The Company recently launched clonoSEQTM as a CLIA certified Laboratory Developed Test ("LDT") in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.  Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TIL") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQ™.


'/>"/>
SOURCE Adaptive Biotechnologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PI Releases High Power Piezo Amplifier to Drive Adaptive Structures, Fast Tool Servos, Vibration Cancellation Systems – Model E-482
2. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
3. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
4. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
5. Dr. Gerald Jerry Zon Launches New Blog for TriLink BioTechnologies
6. TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S, Copenhagen, Denmark
7. TriLink BioTechnologies Awards Keck Science Department ResearchReward
8. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
9. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
10. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
11. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ... "Emotion Detection and Recognition Market by ... Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020" report ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition of ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
Breaking Biology News(10 mins):